3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Breast Neoplasms
13
Neoplasm Metastasis
9
Stomach Neoplasms
5
Endometrial Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Adenocarcinoma
3
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Melanoma
1
Interventions
Oxaliplatin
8
Fluorouracil
8
pembrolizumab
7
Paclitaxel
6
Trastuzumab
5
Leucovorin
5
Capecitabine
5
Specimen Handling
4
Radiation
4
Cisplatin
4
Carboplatin
4
tislelizumab
3
patritumab deruxtecan
3
Taxes
3
Radiotherapy
3
Nivolumab
3
ulixertinib
2
trastuzumab deruxtecan
2
trastuzumab biosimilar HLX02
2
durvalumab
2
Surgical Procedures, Operative
2
Ramucirumab
2
Pemetrexed
2
PF-05280014
2
Ontruzant
2
Ogivri
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Immunotherapy
2
Exercise
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
trastuzumab deruxtecan
×
30 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled
NCT04379596
2026-05-13
DG-03
AstraZeneca
Phase 2
Recruiting
450 enrolled